Jefferies raised the firm’s price target on Novartis to $122.50 from $121 and keeps a Buy rating on the shares. The firm’s Q2 sales forecast is 2% above consensus and it sees 6%-8% higher profits, which “may enable another beat-and-raise,” the analyst tells investors in a preview note for the EU pharma group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- MorphoSys and Novartis sign delisting agreement
- Novartis announces its Phase III study of Scemblix showed ‘superior efficacy’
- Novartis says Phase III data confirm efficacy, safety of oral remibrutinib
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Novartis initiated with a Buy at Goldman Sachs